As Abbott Labs Com (ABT) Market Valuation Declined, First Long Island Investors LLC Has Increased by $7.22 Million Its Holding

February 15, 2018 - By Louis Casey

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It fall, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. First Bancshares owns 167,570 shares. First Interstate Bancorp holds 0.08% of its portfolio in Abbott Laboratories (NYSE:ABT) for 6,665 shares. 3,905 are owned by Cohen Lawrence B. M Kraus And Com reported 2.58% of its portfolio in Abbott Laboratories (NYSE:ABT). Wealthfront Inc holds 0.04% of its portfolio in Abbott Laboratories (NYSE:ABT) for 55,438 shares. Destination Wealth owns 247,851 shares. Tributary Cap Management Limited Liability reported 1,980 shares. Contravisory accumulated 917 shares. Bragg Financial Advsr Inc owns 0.55% invested in Abbott Laboratories (NYSE:ABT) for 67,464 shares. Ing Groep Nv accumulated 0.01% or 12,180 shares. Victory Cap Mgmt reported 0% of its portfolio in Abbott Laboratories (NYSE:ABT). New York-based Trustco Bank & Trust Corporation N Y has invested 1.94% in Abbott Laboratories (NYSE:ABT). Wellington Management Grp Limited Liability Partnership owns 51.17 million shares. Moreover, Fukoku Mutual Life Ins has 0.08% invested in Abbott Laboratories (NYSE:ABT). 6,883 were accumulated by Bancorpsouth Inc.

Since August 16, 2017, it had 0 insider buys, and 7 sales for $31.71 million activity. Fussell Stephen R had sold 196,550 shares worth $9.73 million. Salvadori Daniel Gesua Sive sold $1.56M worth of stock or 28,319 shares. Shares for $2.69 million were sold by Ford Robert B on Tuesday, January 30. Another trade for 52,700 shares valued at $2.74M was made by Contreras Jaime on Friday, September 22.

First Long Island Investors Llc increased its stake in Abbott Labs Com (ABT) by 48.18% based on its latest 2017Q3 regulatory filing with the SEC. First Long Island Investors Llc bought 136,242 shares as the company’s stock declined 3.42% while stock markets rallied. The hedge fund held 419,046 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $22.36 million, up from 282,804 at the end of the previous reported quarter. First Long Island Investors Llc who had been investing in Abbott Labs Com for a number of months, seems to be bullish on the $103.31 billion market cap company. The stock increased 1.84% or $1.07 during the last trading session, reaching $59.35. About 2.18 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 15, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: which released: “Abbott Laboratories (ABT) a Buy at recent price of $63.22, on Robust Earnings …” on January 26, 2018, also with their article: “Capital Research Global Investors Buys Nike Inc, Abbott Laboratories, Gilead …” published on February 15, 2018, published: “Abbott’s fourth-quarter results, 2018 profit forecast beat estimates” on January 24, 2018. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: and their article: “St. Jude Medical delivers sales growth for Abbott Labs” published on January 25, 2018 as well as‘s news article titled: “Abbott Laboratories expected to post earnings of 73 cents a share – summary” with publication date: January 22, 2018.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. BMO Capital Markets upgraded the shares of ABT in report on Tuesday, December 12 to “Outperform” rating. William Blair upgraded Abbott Laboratories (NYSE:ABT) on Thursday, January 25 to “Buy” rating. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. The rating was maintained by Stifel Nicolaus on Friday, September 22 with “Buy”. The firm earned “Buy” rating on Monday, June 26 by RBC Capital Markets. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) on Thursday, July 23 with “Buy” rating. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) rating on Wednesday, January 24. Stifel Nicolaus has “Buy” rating and $71.0 target. The rating was upgraded by Edward Jones on Tuesday, June 21 to “Buy”. On Wednesday, October 7 the stock rating was upgraded by Barclays Capital to “Overweight”. As per Thursday, August 17, the company rating was initiated by Citigroup.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.